MBS8
Checkpoint-resistant solid tumors (focus on melanoma)
Phase 1b/2Active
Key Facts
Indication
Checkpoint-resistant solid tumors (focus on melanoma)
Phase
Phase 1b/2
Status
Active
Company
About MonTa Biosciences
MonTa Biosciences is advancing MBS8, a second-generation systemic Toll-like receptor 7 (TLR7) agonist, as a potential best-in-class asset for cancer immunotherapy. The company has completed a Phase I safety study, established a recommended dose, and initiated an expansion study in checkpoint-resistant melanoma in Denmark and Spain. MonTa's technology is designed to turn immunologically 'cold' tumors 'hot' and restore responsiveness to PD-1 inhibitors, positioning it in a TLR7 field with strong clinical validation and investor interest.
View full company profile